Mansha Kahloon, MD
Interventional Cardiology · Morehead, KYNPI 1265498745
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,343 of the $13,779 with a category attached, or 60.5%. 32 manufacturers reported payments, led by Abbott at 54.4% of the total. Reporting peaked in 2023 at $4,861 and has fallen 75.8% since, to $1,176 in 2025.
Across 385 payments — averaging $35.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Novartis$1K
- Terumo Medical Corporation$826
- Pfizer$794
- AstraZeneca$704
- Amgen$681
- plus $2K from 26 others
What the payments were for
- Travel & lodging$5,42239%
- Food & beverage$8,34361%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 63 | $7,490 |
| Novartis | 79 | $1,362 |
| Terumo Medical Corporation | 9 | $826 |
| Pfizer | 59 | $794 |
| AstraZeneca | 35 | $704 |
| Amgen | 37 | $681 |
| Merck | 19 | $340 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $318 |
| Johnson & Johnson | 14 | $273 |
| Boehringer Ingelheim | 6 | $128 |
| Novo Nordisk | 5 | $112 |
| Biotronik Inc. | 5 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Boston Scientific | 3 | $65 |
| Cvrx, Inc. | 1 | $57 |
| Inari Medical, Inc. | 2 | $55 |
| Bayer | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Shockwave Medical, Inc | 2 | $37 |
| Kestra Medical Technology Services, Inc. | 1 | $37 |
| Atricure, Inc. | 2 | $32 |
| Medtronic | 2 | $29 |
| Cook Medical LLC | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Acacia Pharma Inc | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,779 in reported general payments places this provider in the 65th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,064 | $1,038,489 |
| XareltoRivaroxaban | 534 | $559,894 |
| EntrestoSacubitril/Valsartan | 294 | $291,800 |
| Repatha SureclickEvolocumab | 271 | $191,188 |
| FarxigaDapagliflozin Propanediol | 167 | $165,349 |
| Praluent PenAlirocumab | 77 | $52,993 |
| MultaqDronedarone Hcl | 43 | $46,799 |
| BrilintaTicagrelor | 82 | $42,355 |
| JardianceEmpagliflozin | 39 | $39,531 |
| Dofetilide | 201 | $27,991 |
| DapagliflozinDapagliflozin Propanediol | 34 | $18,867 |
| VascepaIcosapent Ethyl | 28 | $17,841 |
| NexletolBempedoic Acid | 14 | $14,052 |
| Labetalol Hcl | 608 | $12,946 |
| Flecainide Acetate | 241 | $11,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $794 | $1,038,4891,064 claims |
| Johnson & JohnsonXarelto | $273 | $559,894534 claims |
| NovartisEntresto | $1,362 | $291,800294 claims |
| AstraZenecaFarxiga, Brilinta | $704 | $207,704249 claims |
| Sanofi-aventis U.S. LLCMultaq | $42 | $46,79943 claims |
| Boehringer IngelheimJardiance | $128 | $39,53139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Morehead
- Ayita RayMorehead$9K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.